• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
DeviceVISX EXCIMER LASER SYSTEM MODELS B AND C
Classification Nameexcimer laser system
Generic Nameexcimer laser system
Applicant
AMO Manufacturing USA, LLC
510 cottonwood drive
milpitas, CA 95035
PMA NumberP930016
Supplement NumberS005
Date Received07/23/1997
Decision Date01/29/1998
Product Code
LZS[ Registered Establishments with LZS ]
Docket Number 99M-0293
Notice Date 07/15/1999
Advisory Committee Ophthalmic
Supplement Typepanel track
Supplement Reason labeling change - indications/instructions/shelf life/tradename
Expedited Review Granted? Yes
Combination Product No
Approval Order Statement 
Approval for the visx excimer laser system (models b and c). This device is indicated for myopic and astigmatic prk using an ablation zone with a 6. 0 mm major axis. The prk procedure is intended for use: 1)in patients with documented evidence of a change in manifest refraction of less than or equal to 0. 5d (in both cylinder and sphere components) per year for at least one year prior to the date of the pre-operative examination; and 2) in patients 18-20 years of age in prk treatments for the reduction or elimination of myopia (nearsightedness) of less than or equal to -6. 0 d spherical equivelent at the corneal plane with less than or equal to -1. 0 d of astigmatism; or 3) in patients 21 years of age or older in prk treatments for the reduction or elimination of myopia (nearsightedness) of between 0 and -12. 0 d spherical myopia at the spectacle plane and up to -4. 0 d of astigmatism.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
-
-